Comparison between Agilus Diagnostics IPO and Shiprocket IPO.
Agilus Diagnostics IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Shiprocket IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Agilus Diagnostics IPO is up to ₹0.00 Cr whereas the issue size of the Shiprocket IPO is up to ₹2,342.35 Cr. The final issue price of Agilus Diagnostics IPO is and of Shiprocket IPO is .
| Agilus Diagnostics IPO | Shiprocket IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ||
| Issue Price (Upper) | ||
| Issue Price (Final) | ||
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | ||
| Fresh Issue Size | 0 shares | 0 shares |
| Fresh Issue Size (Amount) | up to ₹0.00 Cr | up to ₹1,100.00 Cr |
| OFS Issue Size | 1,42,33,964 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹1,242.35 Cr |
| Issue Size Total | 1,42,33,964 shares | 0 shares |
| Issue Size Total (Amount) | up to ₹0.00 Cr | up to ₹2,342.35 Cr |
Agilus Diagnostics IPO opens on , while Shiprocket IPO opens on . The closing date of Agilus Diagnostics IPO and Shiprocket IPO is , and , respectively.
Agilus Diagnostics IPO P/E ratio is , as compared to Shiprocket IPO P/E ratio of .
| Agilus Diagnostics IPO | Shiprocket IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)
| Company Financials (Restated Consolidated)Shiprocket Ltd.'s revenue increased by 23% and profit after tax (PAT) rose by 87% between the financial year ending with March 31, 2025 and March 31, 2024.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 57.68 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 6.12% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 20.17% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 6.61% | -4.99% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Agilus Diagnostics IPO Retail Individual Investors (RII) are offered while in Shiprocket IPO retail investors are offered . Qualified Institutional Buyers (QIB) are offered in Agilus Diagnostics IPO and 0 shares in Shiprocket IPO.
| Agilus Diagnostics IPO | Shiprocket IPO | |
|---|---|---|
| Anchor Investor Reservation | 0 shares | |
| Market Maker Reservation | 0 shares | |
| QIB | 0 shares | |
| NII | 0 shares | |
| RII | 0 shares | |
| Employee | 0 shares | |
| Others | ||
| Total | 0 shares |
Agilus Diagnostics IPO subscribed in total, whereas Shiprocket IPO subscribed .
| Agilus Diagnostics IPO | Shiprocket IPO | |
|---|---|---|
| QIB (times) | ||
| NII (times) | ||
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | ||
| Employee (times) | ||
| Other (times) | ||
| Total (times) |
